Jun 15, 2017 | Staff Reporter
NEW YORK (GenomeWeb) – Human Longevity (HLI) announced today that it has partnered with Germany’s Merck KGaA to identify treatment-response biomarker signatures in patients with advanced melanoma. In a pilot project, the companies will look for these biomarkers in patients with locally advanced or metastatic NRAS-mutated cutaneous melanoma who preferentially respond to Merck’s MEK1/2 inhibitor pimasertib. As part of the effort, HLI said it will generate genomic sequencing data from clinical trial participants’ tumors and germline DNA, then use its machine learning and analytical technologies to analyze the data in the context of survival and other clinical data.
RELATED STORY | CONCIERGE MEDICINE TODAY
HEALTH DECISION SUPPORT TOOLS, 2017-2018 – New Collaboration Between CMT & MPIRICA … Offers Over One Million Surgeon Quality Scores, An Industry First — Read Full Press Release Here >